How a global healthcare network built around independent agencies and affiliations can beat the Holding Companies at their own game
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.
Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
GlaxoSmithKline inked deals earlier this year to support the development of multiple adjuvanted COVID-19 vaccine candidates and has now pledged to manufacture 1 billion doses of that efficacy-boosting system by 2021.
Startup company ViralClear Pharmaceuticals’ broad-spectrum antiviral drug merimepodib is about to enter Phase II studies for COVID-19.
Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.
A protein called ACE2 is intimately involved in how SARS-CoV-2, the virus that causes COVID-19, infects the body.
The FDA found high levels of the same type of carcinogen that led to the recall of some hypertension and heartburn medications in some of the extended-release version metformin drugs that had been tested.
U.S. drugmaker Pfizer Inc. signed a long-term agreement with glass maker Corning Inc. to procure vials for storing drugs.
The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag.